Sunbelt Securities Inc. Has $45,000 Position in Moderna, Inc. (NASDAQ:MRNA)

Sunbelt Securities Inc. cut its position in Moderna, Inc. (NASDAQ:MRNA) by 35.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 669 shares of the company’s stock after selling 360 shares during the quarter. Sunbelt Securities Inc.’s holdings in Moderna were worth $45,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC acquired a new stake in Moderna during the 2nd quarter worth approximately $26,000. Family Firm Inc. acquired a new position in shares of Moderna during the second quarter worth $33,000. Hanseatic Management Services Inc. acquired a new position in shares of Moderna during the second quarter worth $48,000. Plato Investment Management Ltd grew its stake in shares of Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after purchasing an additional 288 shares during the last quarter. Finally, Larson Financial Group LLC increased its holdings in Moderna by 1,753.1% in the second quarter. Larson Financial Group LLC now owns 593 shares of the company’s stock valued at $70,000 after purchasing an additional 561 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of analyst reports. UBS Group reduced their price target on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Piper Sandler reissued an “overweight” rating and set a $69.00 target price (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. Wolfe Research started coverage on shares of Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target for the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a research note on Thursday, September 19th. Finally, Jefferies Financial Group lowered their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $79.50.

Moderna Price Performance

Shares of MRNA opened at $41.83 on Monday. The business’s fifty day moving average is $48.26 and its 200 day moving average is $83.22. Moderna, Inc. has a 12-month low of $35.80 and a 12-month high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The stock has a market cap of $16.10 billion, a P/E ratio of -7.19 and a beta of 1.58.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm earned ($1.39) earnings per share. Sell-side analysts anticipate that Moderna, Inc. will post -9.3 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,379 shares of company stock worth $158,195. Insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.